Evidence map›Paper›PMID 31021353›Full record

ArticleChemical communications (Cambridge, England)2019

Photo-controlled delivery of a potent analogue of doxorubicin.

Patrick S Dupart, Koushambi Mitra, Charles E Lyons, Matthew C T Hartman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. ACS pharmacology & translational science · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Patrick S DupartDepartment of Chemistry, Virginia Commonwealth University, 1001 W Main St, Richmond, 23284, VA, USA. mchartman@vcu.edu and Massey Cancer Center, Virginia Commonwealth University, 401 College St, Richmond, 23219, Virginia, USA.
Koushambi MitraDepartment of Chemistry, Virginia Commonwealth University, 1001 W Main St, Richmond, 23284, VA, USA. mchartman@vcu.edu and Massey Cancer Center, Virginia Commonwealth University, 401 College St, Richmond, 23219, Virginia, USA.ORCID http://orcid.org/0000-0003-4325-453X
Charles E LyonsMassey Cancer Center, Virginia Commonwealth University, 401 College St, Richmond, 23219, Virginia, USA.
Matthew C T HartmanDepartment of Chemistry, Virginia Commonwealth University, 1001 W Main St, Richmond, 23284, VA, USA. mchartman@vcu.edu and Massey Cancer Center, Virginia Commonwealth University, 401 College St, Richmond, 23219, Virginia, USA.ORCID http://orcid.org/0000-0003-0210-1422

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Light-targeted drug deliveryR15CA167582 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HARTMAN, MATTHEW C · 2012 to 2012
$418k
NCI NIH HHS P30 CA016059NCI NIH HHS R15 CA167582
6 · The paper itself

Abstract

Highly cytotoxic agents have found an important niche in targeted anticancer therapy. Here we develop a new light release strategy for the targeting of one of these agents, 2-pyrrolinodoxorubicin, showing dramatic enhancements in toxicity with light and single digit nM potency.

Indexed as

Antineoplastic AgentsCell Line, TumorCell SurvivalDoxorubicinDrug CarriersDrug LiberationDrug Resistance, NeoplasmHumansUltraviolet RaysAntineoplastic AgentsDoxorubicinDrug Carriers

Identifiers

PMID31021353
PMCPMC6643956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.